For the past half-century the malaria parasites of humans have been under tremendous selection pressure to evolve mechanisms of resistance to the prevailing antimalarial drugs. Chloroquine, and increasingly sulfadoxine-pyrimethamine (SP), have become largely ineffective as monotherapy for the treatment of Plasmodium falciparum malaria in much of the world. The World Health Organization (WHO) now recommends artemisinin-based combination therapy (ACT) as first line treatment for all P. falciparum malaria in endemic areas 1 .
ACTs are efficacious, rapidly acting, well-tolerated and safe. They are available in various formulations which are generally given over three days. ACTs are effective against both asexual and early sexual parasite stages 2 , and thereby reduce transmissibility 3, 4 . The contribution of reduced transmissibility of individual treated infections to overall transmission depends on the proportion of transmissible infections that are treated and the degree of 'saturation' in the transmission dynamics.
So far, significant in-vivo resistance to artemisinin derivatives has not yet been confirmed, and stable resistance has been very difficult to produce in the laboratory 5 .
As for any combination therapy, which involves two effective drugs from different classes, both component drugs protect each other from the development of drug resistance whilst present at effective concentrations. This should prolong their useful lifespan provided that the individual components are not widely available as monotherapies 6 .
Although malaria-endemic countries are switching to ACTs with increasing momentum, even at prices as low as US$1 per dose they are still too costly for communities and governments in poorer countries (5 -10 times higher than the prices of chloroquine or SP in Africa 7 ) . Doubts have been raised about their actual operational effectiveness when they are implemented in "real-life" situations, where infrastructures are weak, access to health care is poor, and there is widespread inappropriate use of antimalarial drugs 8 . Although providing easy access to very low cost ACTs in the private sector or free ACTs in the public sector may achieve this aim, it has to be balanced against the costs and risks of their widespread use. In particular, if artemisinins are used on their own and not in co-formulation with an effective partner drug, then there is a much greater risk of drug resistance arising to this precious class of drugs. Questions remain about the choice of combination therapy and timing of policy change. Finally, an important additional benefit of ACTs in low-transmission areas is their potential ability to reduce malaria transmission and thus the incidence of malaria. Enthusiasm for their deployment in high transmission settings is tempered by the expectation that their deployment is less likely to translate into reduced malaria incidence in these settings.
Modelling transmission dynamics and the spread of antimalarial drug resistance
The development of drug resistance is a two-step process, the de novo or the initial emergence of resistance and its subsequent spread. Resistance spreads because of the higher reproductive rate of resistance infections in the presence of antimalarial drugs. In this paper, we focus on modeling the spread of resistance assuming that drug resistance has already emerged among the human population. Combinations prevent resistance by preventing de novo emergence. Modeling the de novo emergence of drug resistance is discussed elsewhere 9, 10 .
Whilst there is a long history of modelling malaria epidemiology [11] [12] [13] (and the population genetics of drug resistance 10,14,15 16 ) none of the existing models incorporate all the important pharmacological, epidemiological, parasitological, and human behavioural factors that affect the effectiveness of drugs, the development of drug resistance, and the transmission of malaria. More recent models have become more realistic although they were not developed primarily to study drug resistance [17] [18] [19] [20] [21] . We developed a complete model of the spread of antimalarial drug resistance, which incorporates all the important epidemiological factors, and we use it to evaluate different antimalarial policy options focusing on ACT deployment in low and high transmission settings.
This is a data-driven model; the model parameters for mosquito dynamics, malaria infection in the human host (asymptomatic, symptomatic and recrudescent infections) and immunity functions were obtained from clinical, laboratory and epidemiological studies and appropriate model fitting was then performed (Supplementary Information A) .
At the outset, we assume a human population which has little or no exposure to malaria and therefore the population has no immunity to malaria. Infected mosquitoes bite randomly and infect humans with drug susceptible infections and a monotherapy is the only available treatment. As the population becomes exposed to malaria and gains some level of immunity, the model updates the age-stratified immunity of the population according to the Entomological Inoculation Rate (EIR) (which varies with vectorial capacity and the infective human population (see equation 8, Supplementary Information B)), and is allowed to run until a steady state is reached (Figure 1 ). At this point, resistance to the monotherapy is introduced and ACTs are deployed when resistance reaches a specified threshold. Resistance can then be tracked for a specified length of 10 years after steady state to gauge the impact on model outcomes over time. The model provides a number of outputs but we concentrate here on those relevant to policy. We present the proportion of infections with resistant parasites, the malaria prevalence, and the incidence of malaria. Results of sensitivity analyses are presented in Supplementary Information C.
Results

Resistance, Transmission Intensity and ACT coverage
We explore model consistency and model sensitivity from the Coefficient of Mean resistance increases at a slower rate than in a low coverage setting, reaching 80% in year 10. Compared to scenario A, variation in the estimated prevalence is slightly lower (CV ~ 75%) while variation in the rate of resistance is higher (CV > 30%). This indicates some levels of uncertainty in the consequences of deploying a high coverage of ACT on the malaria prevalence and the rate of resistance. Once resistance to the slowly eliminated partner drug has emerged the spread of drug resistance and the malaria prevalence could be slowed down only by deploying ACTs at a high coverage rate while the resistance prevalence is still reasonably low.
In the low transmission setting, Vectorial Capacity ( In the low transmission setting, treatment dependent parameter values are given in Table A8 , Supplementary Information A. The force driving resistance comes from two sources; the first is from symptomatic malaria infections failing treatment and the second is exposure of infections to residual drug taken for presumptive or previous malaria treatment. More than 85% of all infections are symptomatic and thus treated. The rate of spread of resistance is faster relatively to the high transmission setting where treatment failure was identified to be the main force driving the spread of resistance. Deploying a high coverage of effective treatment, such as an ACT, when the level of resistance is still low delays the spread of drug resistance, a result consistent with previous results from simple epidemiological models 22 .
In the high transmission settings, immunity prevents most acquired infections transmitting (and synergises with antimalarial drugs). Approximately 94% of all infections are asymptomatic and untreated. In the absence of antimalarial treatment, the resistant infections have no survival advantage over the sensitive ones, and may have a fitness disadvantage. The main driving force for resistance is created from the selective filter provided by people carrying low residual concentrations of drugs, which protect against the establishment of new sensitive infections but not the resistant ones 23, 24 . Without this residual drug effect, the rate of resistance would be much lower than shown in Figure 2b . Residual drug levels come mainly from previous 'presumptive' treatments (normally for other febrile illness), and are largely unrelated to the peaks of parasitemia 9 and are thereby assumed to have little or no influence on the de novo resistance selection probability.
Combining an artemisinin with a drug to which resistance has arisen delays the spread in resistance in the low transmission setting (Figure 2a and 3a) but this delay decreases exponentially the later the switch is made to the ACT. By contrast, in the high transmission setting (Figure 2b and 3b) , varying the time to switch to the ACT has only a small impact on delaying the spread of resistance.
Scenario B: Effects on artemisinin resistance of different levels of ACT coverage
In this scenario we assume that the monotherapy is the artemisinin and that drug resistance emerges to the artemisinin compound, rather than to the partner drug in an ACT (e.g. either piperaquine or lumefantrine), which is assumed to remain effective (see Table A8 , Supplementary Information A) . This simulates the current scenario in places such as Cambodia where artesunate monotherapy use is widespread 25 . We assume that the switch to the combination therapy is made when the resistance to artemisinin is as low as 1% (Figure 4) . If the switch is made very early, when there are still very few cases of drug resistance, then the higher the coverage with the ACT, the greater is the delay in the spread of resistance. At coverage rates of >80%, the level of resistance to the artemisinin does not reach 50% within the time span of 10 years. In general, the impact of ACT deployment on malaria incidence and prevalence is as expected. By deploying ACTs at a high coverage, the prevalence of malaria can be kept at a very low level over time (0.5%) and incidence is less than 50 cases per year, indeed in the model eradication is only prevented by the influx of malaria in immigrants ( Figure 5 ). Similar to the first scenario, the impact of ACT in the high transmission setting is much less.
The model shows that deploying ACT in a high transmission setting has a small impact on the spread of resistance and malaria prevalence. However, as one of the model outcomes (results not shown), treatment failure in both low and high transmission settings can be sustained to a low level by deploying high ACT coverage (25% of recrudescence compared with 10% when deploying high ACT coverage at year 10). In order to make an impact on malaria transmission and resistance, vector control strategies need to be applied to reduce the vectorial capacity. Reduction in the transmission intensity results in fewer infections which, as host immunity declines, are more likely to be symptomatic and eventually this makes malaria control by drugs more effective. This has important implications for eliminating malaria 28, 29 .
The question of whether it is possible to reduce malaria transmission sufficiently to eliminate malaria eventually in high malaria transmission areas remains antimalarial treatments available and affordable even to the poorest people 30 .
Stabilizing demand for ACT would also create incentives for ACT production, resulting in lower prices 7 .
Methods
Model development and parameter estimation
We model transmission and antimalarial drug resistance using a dynamic, age- on the average parasite biomass by age group and the estimated gametocyte switch rate (i.e. probability that an asexual parasite develops to a sexual parasite). The size and age-structure of the human population was assumed to be constant over time in the model and was based on an average African age-structure (http://esa.un.org/unpp).
The model handles malaria like a "macro" parasite by quantifying the density of infection in the human host. The in-vivo effect of drugs on parasite density can be measured, allowing quantification of the pharmacodynamic properties of antimalarial drugs 33 . Different multiple linear and non-linear regressions equations as a function of age and EIR were fitted to data from age-stratified epidemiological studies in areas with different transmission intensities. Stepwise selection using the Akaike Information Criteria (AIC) was used to identify the best fit in the case of non-nested functions and the maximum-likelihood ratio test was used for nested functions. These relationships represent the development of immunity with age and malaria exposures.
Different facets of malaria immunity are incorporated into this model ( Figure 6) i.e.
reducing host susceptibility to infection 34, 35 , reducing the level of (largely asymptomatic) parasitemia in infected people 36, 37 , reducing the likelihood of fever and other symptoms in infected patients [38] [39] [40] , reducing the treatment failure rate for a particular level of antimalarial drug resistance [41] [42] [43] [44] [45] [46] , and increasing the recovery rate of an established infection i.e. shortening the duration of infection [47] [48] [49] (Table A7, Supplementary Information A). Some immunity functions were not measured directly from epidemiological studies (i.e. host susceptibility, duration of infections and treatment failure), so a normalized function of age-stratified parasite density was used to estimate the relationship between age and host susceptibility and between age and duration of infections by specifying initially the "maximum host susceptibility" in a non-immune person and the "maximum duration" of treated and untreated infections.
The host susceptibility and the duration of infection for any given age group in any transmission intensity setting are then determined by the shape of the immunity curve.
As the shape of the age effect on treatment failure is similar to the relationship between age and severe malaria 41 , we apply the same technique to the normalized function of age-stratified risk of severe malaria to adjust the treatment failure rates for any given age group in any transmission intensity setting. The maximum value of duration of infection and the maximum value of treatment failure are dependent on treatment type, drug resistance, and patient adherence to therapy.
For simplicity, the gametocyte switching rate (GSR) was assumed to be uniform among asexual parasites and infections but to vary depending on the type of drug, and also between primary and recrudescent infections. It is assumed that all humans are equally attractive to biting mosquitoes and that all mosquito biting vectors are equally susceptible i.e. the infectiousness to mosquitoes is assumed to be determined solely by the gametocyte density in humans.
To track the rate of spread of resistance, the inoculation rates of resistant and sensitive infections were calculated separately. Thus, the proportion of infected and 
Model simulations and outputs
Malaria infections initially are all drug-sensitive and symptomatic humans receive only monotherapy (drug A). A steady state is defined as the point at which the number of new malaria cases (i.e. excluding imported cases) has varied day to day by less than 1% over a year. When steady state point is reached, the resistance to drug A is introduced, either as importation of a small number of resistant infections or by the de novo emergence of resistance based on available clinical and laboratory data.
Artemisinin or its derivatives, or a completely new drug can also be introduced and which determine the uncertainties of the model outcomes (Table A9 , Supplementary
Information C) and the Partial Rank Correlation Coefficients (PRCCs), which identify influential factors, were calculated (Table A10 , Supplementary Information C). Full technical details can be found in the author's thesis 50 .
Note: Supplementary information is available on the website. 
